image
Healthcare - Biotechnology - NASDAQ - US
$ 1.26
5 %
$ 77.3 M
Market Cap
-0.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PLRX stock under the worst case scenario is HIDDEN Compared to the current market price of 1.26 USD, Pliant Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PLRX stock under the base case scenario is HIDDEN Compared to the current market price of 1.26 USD, Pliant Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PLRX stock under the best case scenario is HIDDEN Compared to the current market price of 1.26 USD, Pliant Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PLRX

image
$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0$4.0$4.0$2.0$2.0$0.0$0.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-228 M OPERATING INCOME
-24.01%
-210 M NET INCOME
-30.35%
-156 M OPERATING CASH FLOW
-33.64%
140 M INVESTING CASH FLOW
210.49%
23.1 M FINANCING CASH FLOW
-91.58%
0 REVENUE
0.00%
-58.9 M OPERATING INCOME
-10.53%
-56.2 M NET INCOME
-12.94%
-48.9 M OPERATING CASH FLOW
-2.52%
69.1 M INVESTING CASH FLOW
76.62%
498 K FINANCING CASH FLOW
388.24%
Balance Sheet Pliant Therapeutics, Inc.
image
Current Assets 362 M
Cash & Short-Term Investments 356 M
Receivables 2.3 M
Other Current Assets 4.24 M
Non-Current Assets 34.7 M
Long-Term Investments 0
PP&E 32.8 M
Other Non-Current Assets 1.92 M
89.61 %8.25 %Total Assets$396.9m
Current Liabilities 33.2 M
Accounts Payable 5.96 M
Short-Term Debt 1.08 M
Other Current Liabilities 26.2 M
Non-Current Liabilities 59.6 M
Long-Term Debt 59.6 M
Other Non-Current Liabilities 0
6.42 %28.18 %64.23 %Total Liabilities$92.9m
EFFICIENCY
Earnings Waterfall Pliant Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 2.12 M
Gross Profit 0
Operating Expenses 228 M
Operating Income -228 M
Other Expenses -18.1 M
Net Income -210 M
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)0(2m)0(228m)(228m)18m(210m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-69.16% ROE
-69.16%
-52.98% ROA
-52.98%
-62.60% ROIC
-62.60%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pliant Therapeutics, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -210 M
Depreciation & Amortization 2.12 M
Capital Expenditures -3.85 M
Stock-Based Compensation 37.6 M
Change in Working Capital 9.09 M
Others 13.6 M
Free Cash Flow -159 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pliant Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for PLRX of $19 , with forecasts ranging from a low of $2 to a high of $38 .
PLRX Lowest Price Target Wall Street Target
2 USD 58.73%
PLRX Average Price Target Wall Street Target
19 USD 1407.94%
PLRX Highest Price Target Wall Street Target
38 USD 2915.87%
Price
Max Price Target
Min Price Target
Average Price Target
40403535303025252020151510105500Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Pliant Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.5 M USD 6
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Pliant Therapeutics Provides Update on BEACON-IPF Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). globenewswire.com - 2 weeks ago
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025. globenewswire.com - 1 month ago
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Activities supporting the close out of BEACON-IPF continue; topline data  expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to  support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2025 financial results. globenewswire.com - 2 months ago
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations -  Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials globenewswire.com - 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
8. Profile Summary

Pliant Therapeutics, Inc. PLRX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 77.3 M
Dividend Yield 0.00%
Description Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Contact 260 Littlefield Avenue, South San Francisco, CA, 94080 https://pliantrx.com
IPO Date June 3, 2020
Employees 171
Officers Dr. Rik Derynck Ph.D. Scientific Founder & Member of Scientific Advisory Board Mr. Bill DeGrado Ph.D. Scientific Founder & Member of Scientific Advisory Board Mr. Christopher S. Keenan Vice President of Investor Relations & Corporate Communications Mr. Johannes P. Hull J.D. Chief Business Officer Dr. Eric A. Lefebvre M.D. Chief Medical Officer Mr. Dean Sheppard M.D. Scientific Founder & Member of Scientific Advisory Board Mr. Hal Chapman M.D. Scientific Founder & Member of Scientific Advisory Board Ms. Delphine Imbert Ph.D. Chief Technical Officer Dr. Keith Lamont Cummings M.B.A., M.D. Chief Financial Officer Dr. Bernard Coulie M.B.A., M.D., Ph.D. President, Chief Executive Officer & Director